Hinge Health, Inc.
HNGE
$89.33
+11.55%
Hinge Health, Inc. is a digital healthcare company that provides a technology platform for the treatment and prevention of joint and muscle pain, leveraging AI-powered motion tracking to deliver musculoskeletal (MSK) care. As a leader in the digital MSK therapy market, Hinge Health differentiates itself through its proprietary patient movement data, which creates a sustainable competitive moat. The company recently went public in May 2025 and is now in a high-growth phase, with revenue accelerating and a clear path to profitability, driven by strong demand for its solutions and expanding client adoption. Investor attention is focused on the company's ability to scale, its AI-driven data advantage, and its recent transition to profitability, which has fueled a significant stock rally.…
HNGE
Hinge Health, Inc.
$89.33
Related headlines
Investment Opinion: Should I buy HNGE Today?
Rating: Buy. Hinge Health is a high-growth company with a clear path to profitability, and the analyst consensus is 'Buy' with an average target of $92.67, implying 15.7% upside. The thesis is supported by accelerating revenue growth (47.23% YoY), a successful turnaround to profitability (net income of $35.1M in Q1 2026), and strong cash generation ($43.0M FCF). The forward P/E of 24.85x is reasonable given the growth rate, and the PS ratio of 6.26x is below its historical average, suggesting the stock is not overvalued relative to its own history.
Sign up to view all
HNGE 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Hinge Health's strong growth, profitability turnaround, and cash generation support a positive outlook. The forward P/E of 24.85x is reasonable given the growth rate, and the stock's PS ratio of 6.26x is below its historical average, suggesting room for upside. However, the medium confidence reflects the stock's high volatility and the risk of growth deceleration. If the company maintains growth above 40% and margins expand, the bullish stance would be upgraded to high confidence. Conversely, if growth falls below 30% or margins compress, the stance would be downgraded to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hinge Health, Inc.'s 12-month outlook, with a consensus price target around $101.67 and implied upside of +13.8% versus the current price.
Average Target
$101.67
0 analysts
Implied Upside
+13.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $140
Analyst target range
Hinge Health is covered by 15 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.56 (where 1 is Strong Buy and 5 is Sell). The average target price is $92.67, implying an upside of 15.7% from the current price of $80.08. The consensus is bullish, with 10 recent ratings from major firms such as Morgan Stanley, KeyBanc, Barclays, and Wells Fargo all at Overweight or Buy, and only one Neutral from Baird. The target price range is $65.00 to $125.00, with the low target implying a downside of 18.8% and the high target implying an upside of 56.1%. The wide spread of $60 suggests significant uncertainty about the company's future growth trajectory. The high target of $125 likely assumes continued rapid revenue growth and margin expansion, while the low target of $65 may reflect concerns about competition or a slowdown in adoption. Recent actions show no downgrades, only reaffirmations of positive ratings, indicating sustained analyst confidence. The wide range and bullish consensus suggest that while analysts are optimistic, there is considerable variability in their expectations, which is typical for a high-growth company in a nascent market.
Bulls vs Bears: HNGE Investment Factors
Hinge Health presents a compelling bull case with accelerating revenue growth (47.23% YoY), a successful profitability turnaround (net income of $35.1M in Q1 2026), and strong cash generation. The bear case centers on valuation concerns (forward P/E 24.85x vs. industry 22x) and the stock's extended run near its 52-week high, which could lead to volatility. Currently, the bull case has stronger evidence given the fundamental improvements and analyst consensus, but the key tension is whether the company can sustain its high growth and margin expansion to justify its premium valuation. If growth decelerates or margins compress, the stock could face significant downside, making the sustainability of growth the most critical factor.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue grew 47.23% YoY to $182.3M, up from $117.3M in Q4 2024, with sequential increases each quarter. This accelerating growth is driven by strong demand for its digital MSK solutions and expanding client adoption.
- Profitability Turnaround Achieved: Hinge Health turned profitable in Q4 2025 with net income of $32.1M, followed by $35.1M in Q1 2026, a dramatic improvement from the $575.7M loss in Q2 2025 (which included a one-time impairment). Operating margin swung from -417.5% to +17.6% in Q1 2026, demonstrating strong operating leverage.
- High Gross Margins with Scalability: Gross margin expanded to 84.6% in Q1 2026, up from 70.3% in Q2 2025, reflecting the scalability of its platform. This high margin provides a solid foundation for future profitability and cash flow generation.
- Strong Cash Generation and Low Debt: The company generated $43.1M in operating cash flow and $43.0M in free cash flow in Q1 2026, with $188.1M cash on hand. Debt-to-equity is minimal at 0.021, providing financial flexibility to fund growth initiatives without leverage risk.
Bearish
- Stock Near 52-Week High: At $80.08, the stock is at 87.5% of its 52-week range (high $91.50), having surged 156.91% in 6 months. This extended run may leave the stock vulnerable to profit-taking and a pullback, especially if growth decelerates.
- Valuation Premium to Industry: Forward P/E of 24.85x is 13% above the industry average of 22x. While justified by growth, any slowdown could lead to multiple compression, as the market may not sustain this premium if growth decelerates.
- High Volatility and Drawdown Risk: Max drawdown of -48.52% indicates significant downside risk. The stock's beta and recent 1-month decline of -10.32% (vs. SPY +2.79%) highlight its sensitivity to market sentiment and potential for sharp corrections.
- Dependence on Continued Growth: The forward P/E of 24.85x relies on sustained high growth. If revenue growth decelerates from the current 47% YoY, the stock could face de-rating, as the market may question the sustainability of its premium valuation.
HNGE Technical Analysis
Hinge Health's stock is in a strong uptrend, with a 1-year price change of +32.25% and a 6-month change of +156.91%. The current price of $80.08 sits at 87.5% of its 52-week range (low $30.08, high $91.50), indicating the stock is trading near its highs, reflecting robust momentum and investor optimism. This positioning suggests the market is rewarding the company's growth and profitability improvements, though it also implies the stock may be vulnerable to profit-taking given its extended run.
Beta
—
—
Max Drawdown
-48.5%
Largest decline past year
52-Week Range
$30-$92
Price range past year
Annual Return
+48.0%
Cumulative gain past year
| Period | HNGE Return | S&P 500 |
|---|---|---|
| 1m | +0.9% | +2.4% |
| 3m | +59.5% | +4.6% |
| 6m | +186.6% | +11.7% |
| 1y | +48.0% | +21.4% |
| ytd | +96.1% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HNGE Fundamental Analysis
Hinge Health's revenue is growing rapidly, with the most recent quarter (Q1 2026) reporting revenue of $182.3 million, a 47.23% year-over-year increase. This growth is accelerating, as revenue has climbed from $117.3 million in Q4 2024 to $182.3 million in Q1 2026, with sequential increases in each quarter. The company's growth is driven by strong demand for its MSK solutions, as evidenced by the 47.23% YoY growth rate, and the expansion of its client base. The company turned profitable in Q4 2025, with net income of $32.1 million, and continued this trend in Q1 2026 with net income of $35.1 million, marking a significant turnaround from the $575.7 million loss in Q2 2025, which included a one-time impairment charge. Gross margins are robust at 84.6% in Q1 2026, up from 70.3% in Q2 2025, reflecting the scalability of its platform. Operating margins have also improved dramatically, from -417.5% in Q2 2025 to 17.6% in Q1 2026, indicating strong operating leverage. Hinge Health's balance sheet is solid, with a debt-to-equity ratio of 0.021, indicating minimal leverage, and a current ratio of 1.47, showing adequate liquidity. The company generated $43.1 million in operating cash flow and $43.0 million in free cash flow in Q1 2026, and has $188.1 million in cash on hand. The negative ROE of -139.6% is due to the large loss in Q2 2025, but the recent profitability suggests this will improve. The company's strong cash generation and low debt position provide financial flexibility to fund growth initiatives.
Quarterly Revenue
$182307000.0B
2026-03
Revenue YoY Growth
+47.2%
YoY Comparison
Gross Margin
84.6%
Latest Quarter
Free Cash Flow
$206166000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HNGE Overvalued?
Given that Hinge Health has positive trailing net income (TTM net income is positive, with Q1 2026 net income of $35.1 million), the primary valuation metric selected is the P/E ratio. The trailing P/E is -8.67, which is not meaningful due to the one-time loss in Q2 2025, but the forward P/E is 24.85, indicating the market expects continued earnings growth. The gap between the negative trailing P/E and the positive forward P/E reflects the company's recent turnaround and the market's expectation of sustained profitability. Compared to the industry average P/E of 22x (from valuation data), Hinge Health's forward P/E of 24.85x represents a 13% premium, which is justified by its superior revenue growth (47.23% YoY) and expanding margins. Historically, the stock's P/E has been volatile, ranging from negative to over 2,000x, but the current forward P/E of 24.85x is near the lower end of its historical range, suggesting the market is pricing in a more normalized earnings profile. The PS ratio of 6.26x is also below its historical average of around 25x, indicating the stock is trading at a discount to its own historical valuation on a sales basis, which could present a value opportunity if growth continues.
PE
-8.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 22x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Hinge Health's financials have improved, but the company's history includes a massive $575.7M loss in Q2 2025, which included a one-time impairment, leading to a negative trailing P/E of -8.67 and ROE of -139.6%. While recent quarters show profitability, the volatility in earnings could persist if the company faces unexpected charges or margin pressures. The company's revenue is concentrated in the digital MSK market, which is still nascent, and any slowdown in client adoption could impact growth. Additionally, the company's operating margin of 17.6% in Q1 2026 is positive but may be vulnerable to increased competition or rising costs, though the high gross margin of 84.6% provides some buffer.
FAQ
The key risks are: (1) Growth deceleration: If revenue growth falls below 30%, the premium valuation could compress, leading to a potential -18.8% downside to the analyst low target of $65. (2) Competitive pressure: The digital MSK market is becoming crowded, with players like Sword Health and Omada, which could pressure pricing and market share. (3) Market volatility: The stock has a max drawdown of -48.52% and a 1-month decline of -10.32% (vs. SPY +2.79%), indicating high sensitivity to market sentiment. (4) Regulatory changes: Healthcare reimbursement policies could impact the company's business model. The most severe risk is a combination of growth slowdown and market de-rating, which could push the stock toward its 52-week low of $30.08.
The 12-month forecast is bullish, with a base case probability of 50% targeting $92.67 (analyst average), a bull case probability of 30% targeting $125 (analyst high), and a bear case probability of 20% targeting $65 (analyst low). The most likely scenario is the base case, which assumes revenue growth remains above 35% and margins continue to expand. The key assumption is that the company sustains its growth trajectory and profitability, which would support the current valuation. If growth accelerates, the stock could reach the bull case, but if growth decelerates, the bear case is possible.
HNGE's forward P/E of 24.85x is 13% above the industry average of 22x, suggesting a slight premium, but this is justified by its superior revenue growth (47.23% YoY) and expanding margins. The PS ratio of 6.26x is well below its historical average of around 25x, indicating the stock is trading at a discount to its own history on a sales basis. The market is pricing in continued high growth and profitability, as evidenced by the positive forward P/E. Overall, the stock is fairly valued relative to its growth prospects, not overvalued, but any slowdown in growth could make it look expensive.
HNGE is a good buy for growth investors with a high risk tolerance, given its 47.23% YoY revenue growth and recent profitability turnaround. The analyst consensus is 'Buy' with an average target of $92.67, implying 15.7% upside. However, the stock is near its 52-week high and has a forward P/E of 24.85x, which is a 13% premium to the industry. The biggest downside risk is a growth deceleration, which could lead to multiple compression and a fall to the analyst low target of $65 (-18.8%). For investors who believe in the long-term potential of digital MSK care, HNGE offers a compelling risk/reward, but it is not suitable for conservative investors.
HNGE is more suitable for long-term investment, given its high growth stage and the nascent digital MSK market. The company has a beta that indicates high volatility, and its 1-month decline of -10.32% shows short-term risk. However, the company's strong fundamentals, including 47.23% revenue growth and positive free cash flow, suggest it can compound value over time. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the growth story to play out. Short-term traders may find opportunities in the stock's volatility, but the risk of sharp corrections is high, as evidenced by the max drawdown of -48.52%.